Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
Neeraj Agarwal(University of Utah), Arun Azad(Peter MacCallum Cancer Centre), Joan Carles(Vall d'Hebron Hospital Universitari), André P. Fay(Pontifícia Universidade Católica do Rio Grande do Sul), Nobuaki Matsubara(National Cancer Center Hospital East), Daniel Heinrich(Innlandet Hospital Trust), Cezary Szczylik(Postgraduate School of Molecular Medicine), Ugo De Giorgi(Istituti di Ricovero e Cura a Carattere Scientifico), Jae Young Joung(National Cancer Center), Peter C.C. Fong(Auckland City Hospital), Éric Voog(Centre Jean Bernard), Robert J. Jones(Beatson West of Scotland Cancer Centre), Neal D. Shore(Carolina Urologic Research Center), Curtis Dunshee(Arizona Pain Specialists), Stefanie Zschäbitz(National Center for Tumor Diseases), Jan Oldenburg(Akershus University Hospital), Xun Lin(Pfizer (United States)), Cynthia G. Healy(Pfizer (United States)), Nicola Di Santo(Pfizer (United States)), Fabian Zohren(Pfizer (United States)), Karim Fizazi(Université Paris-Saclay)
Cited by 488
Abstract
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al.|New England Journal of Medicine|2014|3k